000			02862cam a2200349 a 4500
003			EG-GiCUC
005			20250223031719.0
008			170506s2016 ua d f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.11.23.M.Sc.2016.Ab.I
100	0		_aAbdallah Osama Mahmoud Khalil
245	1	4	_aThe impact of treatment modalities on the outcome in patients with breast cancer younger than or equal to 40 years of age / _cAbdallah Osama Mahmoud Khalil ; Supervised Magda Mahmoud Elmongy , Hanaa Attia , Remoun Ramsis Anees
246	1	5	_aدراسة إكلينيكية للنتائج المترتبة على طرق العلاج المختلفة لأورام الثدى فى السيدات أقل من 40 عاماً
260			_aCairo : _bAbdallah Osama Mahmoud Khalil , _c2016
300			_a92 P. : _bcharts ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Oncology - Clinical
520			_aThis is a retrospective cohort study of the results of different treatment methods of breast cancer patients younger than or equal to 40 years treated at NCI-Cairo university between (2005 - 2013) locoregional treatment was either with breast conservative treatment (BCT), modified radical mastectomy (M), or modified radical mastectomy followed by radiotherapy (MRM+RT). The total number is 655 patients from which 221 patients (33.7) received BCT, 92 patients (14%) underwent MRM and 342 patients (52.2%) underwent MRM followed by RT. Median follow up for all patients was 67 months to detect the impact of these different treatment modalities on the LRR, DM and OS. There was no statistically significant difference between the different treatment modalities on the LRR as the LRR after BCT was 9.5% (21 patients from 221), 10.9% after MRM (10 patients from 92) and 7% after MRM+RT (24 patients from 342), P value 0.381. Higher incidence of LRR was detected in the patients who have negative hormone receptors (10% vs. 5.6% for patients with positive hormone receptors ). Patients who underwent MRM without receiving PORT and who had negative hormone receptors showed higher incidence of LRR (17.8%) compared to patients who underwent MRM then PORT (7.3%) and to those who received BCT (11.6%). Molecular subtypes was available for 176 patients, from which 9 % developed LRR and the highest incidence was for TNBC patients 7 patients out of 55
530			_aIssued also as CD
653		4	_a40 years
653		4	_aCancer breast
653		4	_aYoung age
700	0		_aHanaa Attia , _eSupervisor
700	0		_aMagda Mahmoud Elmongy , _eSupervisor
700	0		_aRemoun Ramsis Anees , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aSamia _eCataloger
942			_2ddc _cTH
999			_c60771 _d60771